PDUFA Old School: Industry Wants User Fees To Get Back To Basics
Executive Summary
Calling the current level of industry financial support for new drug reviews "unseemly," Kay Holcombe, a senior policy advisor at Genzyme, says FDA, industry and other stakeholders need to find a way to refocus PDUFA on its original intent - improving efficiency in the drug review process